AbbVie (ABBV -1.6%) has submitted marketing applications
in the U.S. and Europe seeking approval to use Rinvoq (upadacitinib) 15
mg for the once-daily treatment of adults with active psoriatic
arthritis.
The JAK inhibitor is currently approved in both territories for rheumatoid arthritis.
https://seekingalpha.com/news/3579165-abbvie-files-marketing-applications-for-new-use-of-rinvoq
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.